Computer Aided Diagnostics Cadx MarketSize, Share & Industry Analysis, 2026-2034By TypeBy End UseBy ApplicationBy ComponentBy Deployment Mode

Computer-aided diagnostics software analyzes medical images to flag findings for radiologist review, layered on modalities such as mammography, CT, MRI and ultrasound. Buyers are hospitals, standalone imaging and diagnostic centres, and specialty clinics that need faster, more consistent reads across high imaging volumes. The category spans on-premise workstation software and cloud-hosted algorithms, sold as licensed modules or subscription services alongside the imaging equipment itself.

The global computer aided diagnostics cadx market stood at USD 1.08 billion in 2025. A forecast-period rate of 13.13% takes it to USD 3.302 billion by 2034, and the study reports every year in between, passing USD 0.69 billion in 2020, USD 0.987 billion in 2024, USD 1.231 billion in 2026 and USD 2.016 billion in 2030.

On the type axis, growth rates run from 10.71% for Mammography up to 18.2% for Tomosynthesis. Mammography carries the volume: USD 0.368 billion and 34.07% of revenue in 2025, USD 0.925 billion and 28.01% in 2034. The lines gaining share are Tomosynthesis and Computed Tomography (CT). Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound lose share without losing revenue.

Cut by end use, the largest line is Hospitals: 51.94% of 2025 revenue, worth USD 0.561 billion, and 48.03% at USD 1.586 billion by 2034. Medical diagnostic centres grows faster at 15.53% against 12.24%, moving from 20% of revenue to 23.99% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from North America at 42.04% of 2025 revenue down to Middle East and Africa at 2.96%. North America is worth USD 0.454 billion in 2025 and USD 1.255 billion in 2034; Europe, second at 26.02%, moves from USD 0.281 billion to USD 0.792 billion. Asia Pacific and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is a triangulation of published figures and category proxies, short of a directly sourced total. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five type lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 1.08 billion in 2025 to USD 3.302 billion in 2034, a compound annual rate of 13.13%, having reached USD 0.987 billion in 2024 from USD 0.69 billion in 2020.
• The largest line by type is Mammography, worth USD 0.368 billion and 34.07% of revenue in 2025, rising to USD 0.925 billion and 28.01% by 2034.
• Fastest growth on the type axis belongs to Tomosynthesis: 18.2% a year, USD 0.086 billion to USD 0.396 billion, and a share moving from 7.96% to 11.99%.
• The bull case puts 2034 revenue at USD 3.698 billion and the bear case at USD 2.906 billion, either side of the USD 3.302 billion base case, each with its own stated assumption in the full report.
• North America holds 42.04% of global revenue in 2025 at USD 0.454 billion, the largest of the five regions tracked, and reaches USD 1.255 billion by 2034.
• 81.94% of North America's base-year revenue comes from the United States alone: USD 0.372 billion in 2025, rising to USD 1.004 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three movements define the forecast period in the global computer aided diagnostics cadx market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Tomosynthesis grows faster than Mammography. Between 2026 and 2034, 18.2% growth in Tomosynthesis against 10.71% in Mammography pulls the type mix apart. Shares follow: 7.96% to 11.99% for Tomosynthesis, 34.07% to 28.01% for Mammography. Revenue rises on both sides; USD 0.086 billion to USD 0.396 billion and USD 0.368 billion to USD 0.925 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific and Middle East and Africa. Asia Pacific moves from 23.98% of revenue in 2025 to 30.01% in 2034, worth USD 0.259 billion rising to USD 0.991 billion; Middle East and Africa moves from 2.96% of revenue in 2025 to 3% in 2034, worth USD 0.032 billion rising to USD 0.099 billion. Share moves off the others in turn: North America at 42.04% moving to 38.01%, Europe at 26.02% moving to 23.98%, Latin America at 5% moving to 5%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

A continuation, not an inflection. Fifteen years of revenue run USD 0.69 billion in 2020, USD 0.987 billion in 2024, USD 1.08 billion in 2025, USD 1.231 billion in 2026, USD 2.016 billion in 2030 and USD 3.302 billion in 2034. No year breaks the trajectory, and the 13.13% forecast rate compares with 9.38% recorded over 2020-2025, a continuation, not an inflection. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.

The fastest line decides the blended rate

Separate the 13.13% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 2.906 billion by 2034, against USD 3.302 billion in the base case

What the bull case turns on

The total depends on a single line

42.04% of the global computer aided diagnostics cadx market sits in North America in 2025, worth USD 0.454 billion with USD 1.255 billion projected for 2034. Among the five regions it ranks first by revenue in both years.

Its share moves to 38.01% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 34.07% of 2025 revenue in Mammography, fastest growth of 18.2% in Tomosynthesis. The full report breaks North America out along every axis and by country.

The largest single market in North America is the United States, at USD 0.372 billion in 2025 and USD 1.004 billion in 2034. Carrying 81.94% of the region in the base year, it sets North America's direction instead of merely contributing to it. Regional revenue of USD 0.454 billion in 2025 and USD 1.255 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

the United States buys along the same lines as the market globally; Mammography first at 34.07% of 2025 revenue and 28.01% in 2034, Tomosynthesis fastest at 18.2% on a share moving from 7.96% to 11.99%. With 81.94% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports the United States by type separately.

In the United States, computer-aided diagnostic software is regulated by the Food and Drug Administration as a medical device, most often as software as a medical device under the agency's Center for Devices and Radiological Health. A supplier typically brings such a system to market through premarket notification, demonstrating substantial equivalence to a legally marketed predicate, or through the de novo classification pathway when no suitable predicate exists. Clearance requires validation of the algorithm's performance, software lifecycle documentation consistent with recognized quality system standards, and clear labelling describing the intended use, patient population, and limitations of the diagnostic output. Post-market surveillance obligations continue once the device reaches the market.

The suppliers tracked in this study (Hitachi High Technologies Corporation, Vucomp, Siemens Healthcare, EDDA Technology, McKesson Corporation, iCAD, GE Healthcare, Riverain Technologies, Invio Corporation and Median Technology.) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Mammography at 34.07% of 2025 revenue, and taking Tomosynthesis while it grows at 18.2%. Per-company positioning and share at country level are in the full report only.

7.59% of global revenue is generated in Canada; USD 0.082 billion in 2025, reaching USD 0.251 billion in 2034, and 18.06% of North America.

In Europe, 26.02% of global revenue puts 2025 at USD 0.281 billion rising to USD 0.792 billion in 2034. It is a leading region on this axis, second by revenue throughout the period.

23.98% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the type split tracks the global one; 34.07% of 2025 revenue in Mammography, fastest growth of 18.2% in Tomosynthesis. The full report breaks Europe out along every axis and by country.

34.88% of Europe's base-year revenue comes from Germany; USD 0.098 billion, rising to USD 0.261 billion by 2034. Its 34.88% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 0.281 billion in 2025 and USD 0.792 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Mammography at 34.07% of 2025 revenue, easing to 28.01% by 2034, and the fastest is Tomosynthesis at 18.2%, from 7.96% to 11.99%. Since 34.88% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for Germany appears on its own in the full report.

In Germany, computer-aided diagnostic software is governed by the EU Medical Device Regulation, enforced domestically through the Federal Institute for Drugs and Medical Devices alongside independent notified bodies. Because such software qualifies as a medical device in its own right, a manufacturer must classify the product according to its diagnostic role and risk, then undergo conformity assessment before affixing the CE mark. Technical documentation must show clinical evaluation evidence, adherence to harmonised software and risk-management standards, and a quality management system audited by the notified body. Instructions for use must state the intended clinical purpose and the conditions under which a qualified clinician should interpret the output.

The suppliers tracked in this study (Hitachi High Technologies Corporation, Vucomp, Siemens Healthcare, EDDA Technology, McKesson Corporation, iCAD, GE Healthcare, Riverain Technologies, Invio Corporation and Median Technology.) compete in Germany across the type lines above. Mammography, at 34.07% of 2025 revenue, is where the volume sits, and Tomosynthesis, growing at 18.2%, is where position changes hands over the forecast period. Weighting toward Europe means competing for 26.02% of 2025 global revenue, a base of USD 0.281 billion moving to USD 0.792 billion across the forecast period.

The United Kingdom is sized at USD 0.079 billion in 2025, rising to USD 0.214 billion by 2034; 7.31% of global revenue and 28.11% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 0.056 billion in 2025, rising to USD 0.15 billion by 2034; 5.19% of global revenue and 19.93% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 23.98% of global revenue puts 2025 at USD 0.259 billion with USD 0.991 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 30.01% by 2034, on growth above the market's own 13.13%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Mammography leads here as it does globally, at 34.07% of 2025 revenue, and Tomosynthesis again grows fastest at 18.2%. The full report breaks Asia Pacific out along every axis and by country.

The largest single market in Asia Pacific is China, at USD 0.083 billion in 2025 and USD 0.357 billion in 2034. At 32.05% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 0.259 billion to USD 0.991 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in China follows the type mix reported at global level: Mammography is the largest line at 34.07% of 2025 revenue, moving to 28.01% by 2034, while Tomosynthesis grows fastest at 18.2% and takes its share from 7.96% to 11.99%. Its 32.05% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by type separately.

In China, computer-aided diagnostic software falls under the oversight of the National Medical Products Administration, which classifies medical devices by risk and reviews diagnostic software separately from any hardware it runs on. Because such systems inform diagnostic decisions, they are typically assigned to a higher-risk tier requiring registration testing, clinical evaluation, and a full technical review before market approval is granted. Manufacturers must demonstrate conformity with national medical device quality management requirements and provide labelling and instructions for use in Chinese describing the intended clinical function and its limits. Imported systems additionally require a locally appointed agent to hold the registration on the manufacturer's behalf.

Competition in China runs between the suppliers this study tracks: Hitachi High Technologies Corporation, Vucomp, Siemens Healthcare, EDDA Technology, McKesson Corporation, iCAD, GE Healthcare, Riverain Technologies, Invio Corporation and Median Technology.. Mammography, at 34.07% of 2025 revenue, is where the volume sits, and Tomosynthesis, growing at 18.2%, is where position changes hands over the forecast period. A supplier weighted toward Asia Pacific is competing over a base of USD 0.259 billion in 2025 reaching USD 0.991 billion by 2034, 23.98% of global revenue at the start of that period.

6.76% of global revenue is generated in Japan; USD 0.073 billion in 2025, reaching USD 0.218 billion in 2034, and 28.19% of Asia Pacific.

Within Asia Pacific, South Korea accounts for 15.06% of regional revenue and 3.61% of the global total, worth USD 0.039 billion in 2025 and USD 0.159 billion by 2034.

Latin America holds 5% of the global computer aided diagnostics cadx market in 2025, worth USD 0.054 billion and reaches USD 0.165 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

5% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the type split tracks the global one; 34.07% of 2025 revenue in Mammography, fastest growth of 18.2% in Tomosynthesis. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 0.03 billion in 2025 and USD 0.091 billion in 2034. Its 55.56% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Regional revenue of USD 0.054 billion in 2025 and USD 0.165 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Brazil follows the type mix reported at global level: Mammography is the largest line at 34.07% of 2025 revenue, moving to 28.01% by 2034, while Tomosynthesis grows fastest at 18.2% and takes its share from 7.96% to 11.99%. Since 55.56% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by type for Brazil is reported separately in the full report.

In Brazil, computer-aided diagnostic software is regulated by the National Health Surveillance Agency, known locally as ANVISA, under its framework for software as a medical device. A supplier must classify the product by risk, register it with the agency, and show conformity with applicable national and international standards covering software validation and quality management. Labelling and instructions for use must be provided in Portuguese and must describe the intended diagnostic purpose, the patient population, and the clinical context in which the output is meant to support, not replace, a physician's judgement. Changes made to the algorithm after approval generally require a fresh regulatory filing.

Hitachi High Technologies Corporation, Vucomp, Siemens Healthcare, EDDA Technology, McKesson Corporation, iCAD, GE Healthcare, Riverain Technologies, Invio Corporation and Median Technology. are the suppliers covered in Brazil. Two different problems sit on the same axis: holding Mammography at 34.07% of 2025 revenue, and taking Tomosynthesis while it grows at 18.2%. A supplier weighted toward Latin America is competing over a base of USD 0.054 billion in 2025 reaching USD 0.165 billion by 2034, 5% of global revenue at the start of that period.

1.48% of global revenue is generated in Mexico; USD 0.016 billion in 2025, reaching USD 0.05 billion in 2034, and 29.63% of Latin America.

Middle East and Africa holds 2.96% of the global computer aided diagnostics cadx market in 2025, worth USD 0.032 billion with USD 0.099 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.

Share climbs to 3% by 2034, on growth above the market's own 13.13%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Mammography leads here as it does globally, at 34.07% of 2025 revenue, and Tomosynthesis again grows fastest at 18.2%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.013 billion in 2025 and projected to reach USD 0.04 billion by 2034. At 40.63% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.032 billion in 2025 and USD 0.099 billion in 2034, it is the country the full report breaks out in detail.

Saudi Arabia buys along the same lines as the market globally; Mammography first at 34.07% of 2025 revenue and 28.01% in 2034, Tomosynthesis fastest at 18.2% on a share moving from 7.96% to 11.99%. Since 40.63% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, computer-aided diagnostic software is regulated by the Saudi Food and Drug Authority through its national medical device registration system, which follows a risk-based classification approach aligned with international medical device harmonisation frameworks. A supplier must register the product, classify it according to its diagnostic function, and demonstrate conformity with recognised software and quality management standards before the device can be marketed. Labelling and instructions for use must be provided in Arabic and must set out the intended clinical use, the qualified user, and the limitations of the automated output. Market entry is typically coordinated through a locally registered agent or distributor.

The suppliers tracked in this study (Hitachi High Technologies Corporation, Vucomp, Siemens Healthcare, EDDA Technology, McKesson Corporation, iCAD, GE Healthcare, Riverain Technologies, Invio Corporation and Median Technology.) compete in Saudi Arabia across the type lines above. Mammography, at 34.07% of 2025 revenue, is where the volume sits, and Tomosynthesis, growing at 18.2%, is where position changes hands over the forecast period. Weighting toward Middle East and Africa means competing for 2.96% of 2025 global revenue, a base of USD 0.032 billion moving to USD 0.099 billion across the forecast period.

Within Middle East and Africa, the United Arab Emirates accounts for 25% of regional revenue and 0.74% of the global total, worth USD 0.008 billion in 2025 and USD 0.025 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, End Use, Application, Component, Deployment Mode, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.